Drug news
NICE requestes more information on Jardiance for Type 2 Diabetes - Boehringer
In new draft guidance the National Institute for Health and Care Excellence (NICE) has called for more evidence from Boehringer Ingelheim on Jardiance (empagliflozin) for treating Type 2 Diabetes. The NICE request asks for more information to demonstrate that the new drug is cost effective when compared with other treatments the NHS already provides.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.